Status:

COMPLETED

Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

Lead Sponsor:

Fundacion Infant

Conditions:

COVID

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of 2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of Buenos Aires. ...

Eligibility Criteria

Inclusion

  • \- Age ≥ 75 or age 65-74 with at least 1 of the following comorbidities: arterial hypertension, diabetes, obesity, chronic obstructive pulmonary disease, heart disease, chronic kidney disease
  • Last 48 hours: (A)Axillary temperature ≥ 37.5oC or febrile equivalent, combined with (a) dry cough and/or (b) breathing difficulty and/or (c) odinophagia and/or (d) anosmia/dysgeusia and/or (e) any of the following symptoms: fatigue, anorexia, myalgias or rhinorrhea.
  • Confirmed diagnosis SARS-Cov2 by RT-PCR
  • Give Informed consent

Exclusion

  • Severe respiratory disease
  • Cardiac insufficiency,
  • Chronic renal failure,
  • Primary hypogammaglobulinemias,
  • Myelodysplastic syndromes,
  • Chronic linfoproliferative syndromes,
  • Monoclonal gammapathies,
  • Known hypersensitibility,
  • Active cancer,
  • HIV, HBV or HCV infection,
  • Chronic administration of immunosuppressants,
  • Body transplant history,
  • Chronic liver disease, Chronic lung disease with oxygen requirement.

Key Trial Info

Start Date :

June 4 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2020

Estimated Enrollment :

165 Patients enrolled

Trial Details

Trial ID

NCT04479163

Start Date

June 4 2020

End Date

October 25 2020

Last Update

December 22 2020

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Hospital Militar Central

CABA, Buenos Aires, Argentina, 1426

2

CEMIC

CABA, Buenos Aires, Argentina

3

Centro de Investigacion Clinica OSECAC

CABA, Buenos Aires, Argentina

4

Centro Gallego de Buenos Aires

CABA, Buenos Aires, Argentina

Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 | DecenTrialz